HANGZHOU REGENOVO BIOTECHNOLOGY CO., LTD – Trademark Portfolio

Entity Type: 03

HANGZHOU REGENOVO BIOTECHNOLOGY CO., LTD holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 1 filings in this category. The portfolio also extends into Class 7 (Machinery) across 3 Nice Classification classes. The owner is based in Zhejiang Province.

Room C1101-C1102, Building No.2,

Zhejiang Province , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

REGENOVO
REGENOVO
Abandoned 2017

Trademark Classifications

HANGZHOU REGENOVO BIOTECHNOLOGY CO., LTD's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

9
Computers & Electronics (1 filing)

Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments

7
Machinery (1 filing)

Machines and machine tools; motors and engines; machine coupling and transmission components

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does HANGZHOU REGENOVO BIOTECHNOLOGY CO., LTD have?

HANGZHOU REGENOVO BIOTECHNOLOGY CO., LTD has 1 U.S. trademark filed with the USPTO.

What trademark classes does HANGZHOU REGENOVO BIOTECHNOLOGY CO., LTD file in?

HANGZHOU REGENOVO BIOTECHNOLOGY CO., LTD files trademarks across 3 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 7 (Machinery), Class 10 (Medical Apparatus). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.

What is HANGZHOU REGENOVO BIOTECHNOLOGY CO., LTD's trademark registration success rate?

HANGZHOU REGENOVO BIOTECHNOLOGY CO., LTD has a 0% trademark registration rate, with 0 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.